---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174061"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:24:31.458093+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM

## Summary
- Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.
- Prothena eligible for up to $1.2B in milestones, $100M received to date.
- Clinical milestone payment triggered when prespecified enrollment criteria met in Phase 3.
- Coramitug is a potential first-in-class amyloid depleter antibody.

## SEC filing metadata
- accession: 0001193125-25-174061
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000119312525174061/0001193125-25-174061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000119312525174061/d42243d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174061
- JSON: https://secwatch.observer/filing/0001193125-25-174061.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.